The local hormonal environment of tumor and perifocal zone in patients with breast cancer: data and prospects of their application
https://doi.org/10.17650/1994-4098-2016-12-3-30-35
Abstract
The expression of androgen receptors is maximal in the luminal subtypes of breast cancer (BC) and increases with patient age, except triplenegative cancer cases. In reproductive age and perimenopause, the local hormonal environment of breast tumor is characterized by a 1.3– 2.0-fold predominance of androgens over estrogens (p < 0.05), but in postmenopause it depends on the biological subtype of BC. Only in the reproductive period, local hyperandrogenism is associated with the low expression of androgen receptors. As reproductive function fades away, androgen receptor expression increases and, even in perimenopause, relative hyperandrogenism in the tumor is associated with the high level of their expression. Thus, in addition to the standard immunohistochemical panel, it is also necessary to take into account other determinants of tumor biological behavior and menstrual function in women, in particular the local hormonal status of the tumor in combination with the expression of sex hormones, including androgen receptors, which allows consideration of anti-androgen therapy in treating a certain category of patients with BC.
About the Authors
Yu. S. Shatova
Rostov Research Institute of Oncology, Ministry of Health of Russia
Russian Federation
63 14th Line St., Rostov-on-Don
Russian Federation
63 14th Line St., Rostov-on-Don
E. M. Frantsiyants
Rostov Research Institute of Oncology, Ministry of Health of Russia
Russian Federation
63 14th Line St., Rostov-on-Don
Russian Federation
63 14th Line St., Rostov-on-Don
I. A. Novikova
Rostov Research Institute of Oncology, Ministry of Health of Russia
Russian Federation
63 14th Line St., Rostov-on-Don
Russian Federation
63 14th Line St., Rostov-on-Don
L. N. Vashchenko
Rostov Research Institute of Oncology, Ministry of Health of Russia
Russian Federation
63 14th Line St., Rostov-on-Don
Russian Federation
63 14th Line St., Rostov-on-Don
V. A. Bandovkina
Rostov Research Institute of Oncology, Ministry of Health of Russia
Russian Federation
63 14th Line St., Rostov-on-Don
Russian Federation
63 14th Line St., Rostov-on-Don
M. I. Vereskunova
Rostov Research Institute of Oncology, Ministry of Health of Russia
Russian Federation
63 14th Line St., Rostov-on-Don
Russian Federation
63 14th Line St., Rostov-on-Don
A. N. Khugaeva
Rostov Research Institute of Oncology, Ministry of Health of Russia
Russian Federation
63 14th Line St., Rostov-on-Don
Russian Federation
63 14th Line St., Rostov-on-Don
V. V. Tokmakov
Rostov Research Institute of Oncology, Ministry of Health of Russia
Russian Federation
63 14th Line St., Rostov-on-Don
Russian Federation
63 14th Line St., Rostov-on-Don
References
1. Семиглазов В.Ф. Рак молочной железы: мультидисциплинарный подход к лечению. Практическая онкология 2015;16(2): 49–54. [Semiglazov V.F. Breast cancer: multidisciplinary approach to the treatment. Prakticheskaya onkologiya = Practical Oncology 2015;16(2):49–54. (In Russ.)].
2. Шатова Ю.С. Клинико-эпидемиологические и гормонально-метаболические закономерности развития рака молочной железы у женщин в различные репродуктивные периоды жизни. Автореф. дис. … д-ра мед. наук. Ростов н/Д, 2015. 45 с. [Shatovа Yu.S. Clinical and epidemiological and hormone and metabolic laws of development of the breast cancer at women in different reproductive life periods. Author’s abstract of thesis … of doctor of medicine. Rostov-on-Don, 2015. 45 p. (In Russ.)].
3. Garay J.P., Park B.H. Androgen receptor as a targeted therapy for breast cancer. Am J Cancer Res 2012;2(4):434–45. PMID: 22860233.
4. Adair F.E., Herrmann J.B. The use of testosterone propionate in the treatment of advanced carcinoma of the breast. Ann Surg 1946;123(6):1023–35. PMID: 20987951.
5. Gucalp A., Tolaney S., Isakoff S.J. et al. Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic breast cancer. Clin Cancer Res 2013;19(19):5505–12. DOI: 10.1158/1078-0432.CCR-12-3327. PMID: 23965901.
6. Schwartzberg L.S., Yardley D.A., Elias A.D. et al. Enzalutamide plus exemestane: a pilot study to assess safety, pharmacokinetics, and effects on circulating estrogens in women with advanced hormone-positive breast cancer. ASCO Annual Meeting Proceedings. J Clin Oncol 2014;32(suppl):abstract 545.
7. Cochrane D.R., Bernales S., Jacobsen B.M. et al. Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide. Breast Cancer Res 2014;16(1):R7. DOI: 10.1186/bcr3599. PMID: 24451109.
8. O’Shaughnessy J., Campone M., Brain E. et al. Randomized phase 2 study of abiraterone acetate with or without exemestane in postmenopausal patients with estrogen receptor-positive metastatic breast cancer. ASCO Annual Meeting Proceedings. J Clin Oncol 2014;32(suppl):abstract 519.
9. Anestis A., Karamouzis M.V., Dalagiorgou G., Papavassiliou A.G. Is androgen receptor targeting an emerging treatment strategy for triple negative breast cancer? Cancer Treat Rev 2015;41(6):547–53. DOI: 10.1016/j.ctrv.2015.04.009. PMID: 25944485.
10. Lehmann B.D., Bauer J.A., Schafer J. M. et al. PIK3CA mutations in androgen receptorpositive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors. Breast Cancer Res 2014;16(4):406. DOI: 10.1186/s13058-014-0406-x. PMID: 25103565.
11. Stage 1 results from MDV3100-11: a 2-stage study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor. In: Advanced AR+ triple-negative breast cancer (TNBC) 37th annual San Antonio breast cancer symposium, 2014.
12. von Wahlde M.K., Hülsewig C., Ruckert C. et al. The anti-androgen drug dutasteride renders triple negative breast cancer cells more sensitive to chemotherapy via inhibition of HIF-1α-/VEGF-signaling. Gynecol Endocrinol 2015;31(2):160–4. DOI: 10.3109/09513590.2014.971235. PMID: 25356777.
13. Сметник В.П., Тумилович Л.Г. Неоперативная гинекология. СПб.: Сотис, 1995. С. 221. [Smetnik V.P., Tumilovich L.G. Nonoperative gynecology. Saint Petersburg: Sotis, 1995. P. 221. (In Russ.)].
14. Кит О.И., Шатова Ю.С., Тодоров С.С. и др. Гетерогенность люминального рака молочной железы у женщин с различным репродуктивным статусом. Российский онкологический журнал 2014;6(9):14–7. [Kit О.I., Shatova Yu.S., Тоdorov S.S. et al. Heterogeneity of the luminal breast cancer at women with different reproductive status. Rossiyskiy onkologicheskiy zhurnal = Russian Oncological Journal 2014;6(9):14–7. (In Russ.)].
15. Лазукин А.В. Фактор прогноза Ki-67 как показатель прогноза при раке молочной железы. Российский биотерапевтический журнал 2014;13(2):29–34. [Lazukin А.V. Ki-67 forecast factor as forecast index at the breast cancer. Rossiyskiy bioterapevticheskiy zhurnal = Russian Biotherapeutic Journal 2014;13(2):29–34. (In Russ.)].
16. МанихасА.Г., БабешкинР.Н., ПалтуевР.М., Манихас Г.М. Место неоадъювантной химиотерапии трижды негативного рака молочной железы в Санкт-Петербургском городском клиническом онкологическом диспансере. Опухоли женской репродуктивной системы 2016;12(2):26–34. [Маnikhas А.G., Babeshkin R.N., Paltuev R.М., Маnikhas G.М. Place of non-adjuvant chemical therapy of the triple negative breast cancer in Saint-Petersburg City Clinical Oncologic Dispensary. Opukholi zhenskoy reproduktivnoy sistemy = Tumors of Female Reproductive System 2016;12(2):26–34. (In Russ.)].
17. Демидов С.М., Демидов Д.А., Зафирова М.А. Отдаленные результаты полной клинической и патоморфологической регрессии при раке молочной железы. Опухоли женской репродуктивной системы 2016;12(2):22–5. [Demidov S.М., Demidov D.А., Zafirovа М.А. Remote results of the complete clinical and pathomorphological regression at the breast cancer. Opukholi zhenskoy reproduktivnoy sistemy = Tumors of Female Reproductive System 2016;12(2):22–5. (In Russ.)].
Review
For citations:
Shatova Yu.S., Frantsiyants E.M., Novikova I.A., Vashchenko L.N., Bandovkina V.A., Vereskunova M.I., Khugaeva A.N., Tokmakov V.V. The local hormonal environment of tumor and perifocal zone in patients with breast cancer: data and prospects of their application. Tumors of female reproductive system. 2016;12(3):30-35. (In Russ.) https://doi.org/10.17650/1994-4098-2016-12-3-30-35
Views:
964
Email this article 